PCV 2-Based Methods and Compositions for the Treatment of Pigs
AssigneeVectogen Pty Ltd.
InventorsMichael Sheppard, Sui T. Lay
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods and compositions for vaccinating pigs against porcine circovirus associated diseases.
Claims26
A recombinant expression vector comprising a nucleic acid sequence that encodes a modified PCV2 ORF2 operably linked to a promoter, wherein
- a. the modified PCV2 ORF2 is one in which the nuclear localization signal of wild-type PCV2 ORF2 has been removed or modified to allow secretion of truncated ORF2 protein upon expression;
- or
- b. the modified PCV2 ORF2 is one in which the nuclear localization signal has been removed and replaced with a signal hydrophobic signal that directs expression of the PCV2 ORF2 on the cell surface of an infected cell.
A vaccine for the protection of pigs against diseases caused by PCV-2 ORF2, said vaccine comprising a recombinant virus vector comprising a promoter operably linked to a hydrophobic signal sequence comprising a nucleic acid that encodes a membrane anchoring domain, a multiple cloning site for insertion of a modified PCV-2 ORF2 in frame with said hydrophobic signal sequence, a polyadenylation signal;
- and a viral genome, wherein said modified PCV-2 ORF2 lacks a nuclear localization signal.
A vaccine for the protection of pigs from PCV-2 associated disorder, said vaccine comprising a recombinant porcine adenovirus 3 vector comprising a promoter operably linked to a hydrophobic signal sequence comprising a nucleic acid that encodes a membrane anchoring domain, and a nucleic acid that encodes a truncated PCV2 ORF2 that lacks a NLS sequence inserted in frame with said hydrophobic signal sequence, a polyadenylation signal;
- and a porcine adenovirus 3 genome.
Dependencies are inferred from the claim text.